-
1
-
-
84860873205
-
Targeted therapy in bone and soft tissue sarcoma in children and adolescents
-
P.A. Thompson, and M. Chintagumpala Targeted therapy in bone and soft tissue sarcoma in children and adolescents Curr Oncol Rep 14 2012 197 205
-
(2012)
Curr Oncol Rep
, vol.14
, pp. 197-205
-
-
Thompson, P.A.1
Chintagumpala, M.2
-
2
-
-
79951646505
-
Pharmacotherapy for pediatric soft-tissue sarcomas
-
M. Casanova, and A. Ferrari Pharmacotherapy for pediatric soft-tissue sarcomas Expert Opin Pharmacother 12 2011 517 531
-
(2011)
Expert Opin Pharmacother
, vol.12
, pp. 517-531
-
-
Casanova, M.1
Ferrari, A.2
-
4
-
-
77953019735
-
Targets for cancer therapy in childhood sarcomas
-
M. Wachtel, and B.W. Schafer Targets for cancer therapy in childhood sarcomas Cancer Treat Rev 36 2010 318 327
-
(2010)
Cancer Treat Rev
, vol.36
, pp. 318-327
-
-
Wachtel, M.1
Schafer, B.W.2
-
5
-
-
77956393743
-
New developments in targeted therapy for soft tissue sarcoma
-
K.N. Ganjoo New developments in targeted therapy for soft tissue sarcoma Curr Oncol Rep 12 2010 261 265
-
(2010)
Curr Oncol Rep
, vol.12
, pp. 261-265
-
-
Ganjoo, K.N.1
-
6
-
-
57549092526
-
The tumour microenvironment: A novel target for cancer therapy
-
E. Hanna, J. Quick, and S.K. Libutti The tumour microenvironment: a novel target for cancer therapy Oral Dis 15 2009 8 17
-
(2009)
Oral Dis
, vol.15
, pp. 8-17
-
-
Hanna, E.1
Quick, J.2
Libutti, S.K.3
-
7
-
-
79955528442
-
Extracellular matrix and cell signaling: The dynamic cooperation of integrin, proteoglycan and growth factor receptor
-
S-H. Kim, J. Turnbull, and S. Guimond Extracellular matrix and cell signaling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor J Endocrinol 209 2011 139 151
-
(2011)
J Endocrinol
, vol.209
, pp. 139-151
-
-
Kim, S.-H.1
Turnbull, J.2
Guimond, S.3
-
9
-
-
70149088868
-
Interactions between heparan sulfate and proteins-design and functional implications
-
U. Lindahl, and J.P. Li Interactions between heparan sulfate and proteins-design and functional implications Int Rev Cell Mol Biol 276 2009 105 159
-
(2009)
Int Rev Cell Mol Biol
, vol.276
, pp. 105-159
-
-
Lindahl, U.1
Li, J.P.2
-
10
-
-
84866351573
-
Significance of heparanase in cancer and inflammation
-
I. Vlodavsky, P. Beckhove, I. Lerner, C. Pisano, A. Meirovitz, and N. Ilan Significance of heparanase in cancer and inflammation Cancer Microenviron 5 2011 115 132
-
(2011)
Cancer Microenviron
, vol.5
, pp. 115-132
-
-
Vlodavsky, I.1
Beckhove, P.2
Lerner, I.3
Pisano, C.4
Meirovitz, A.5
Ilan, N.6
-
12
-
-
79952728727
-
Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity
-
V.C. Ramani, Y. Yang, Y. Ren, L. Nan, and R.D. Sanderson Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity J Biol Chem 286 2011 6490 6499
-
(2011)
J Biol Chem
, vol.286
, pp. 6490-6499
-
-
Ramani, V.C.1
Yang, Y.2
Ren, Y.3
Nan, L.4
Sanderson, R.D.5
-
13
-
-
34547313009
-
Mammalian heparanase: What is the message
-
V. Vreys, and G. David Mammalian heparanase: what is the message J Cell Mol Med 11 2007 427 452
-
(2007)
J Cell Mol Med
, vol.11
, pp. 427-452
-
-
Vreys, V.1
David, G.2
-
14
-
-
70449604674
-
Heparin, heparan sulfate and heparanase in inflammatory reactions
-
J-P. Li, and I. Vlodavsky Heparin, heparan sulfate and heparanase in inflammatory reactions Thromb Haemost 102 2009 823 828
-
(2009)
Thromb Haemost
, vol.102
, pp. 823-828
-
-
Li, J.-P.1
Vlodavsky, I.2
-
15
-
-
33748683743
-
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis
-
N. Ilan, M. Elkin, and I. Vlodavsky Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis Int J Biochem Cell Biol 38 2006 2018 2039
-
(2006)
Int J Biochem Cell Biol
, vol.38
, pp. 2018-2039
-
-
Ilan, N.1
Elkin, M.2
Vlodavsky, I.3
-
16
-
-
34250366643
-
Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasis
-
Y. Yang, V. Macleod, H.Q. Miao, A. Theus, F. Zhan, and J.D. Shaughnessy Jr. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis J Biol Chem 282 2007 13326 13333
-
(2007)
J Biol Chem
, vol.282
, pp. 13326-13333
-
-
Yang, Y.1
MacLeod, V.2
Miao, H.Q.3
Theus, A.4
Zhan, F.5
Shaughnessy Jr., J.D.6
-
17
-
-
34247637147
-
Heparanase: A target for drug discovery in cancer and inflammation
-
E.A. McKenzie Heparanase: a target for drug discovery in cancer and inflammation Br J Pharmacol 151 2007 1 14
-
(2007)
Br J Pharmacol
, vol.151
, pp. 1-14
-
-
McKenzie, E.A.1
-
18
-
-
34447287858
-
Heparanase: Structure, biological fnctions and inhibition by heparin-derived mimetics of heparan sulfate
-
I. Vlodavsky, N. Ilan, A. Naggi, and B. Casu Heparanase: structure, biological fnctions and inhibition by heparin-derived mimetics of heparan sulfate Curr Pharm Des 13 2007 2057 2073
-
(2007)
Curr Pharm des
, vol.13
, pp. 2057-2073
-
-
Vlodavsky, I.1
Ilan, N.2
Naggi, A.3
Casu, B.4
-
19
-
-
84861706529
-
Targeting heparanase for cancer therapy at the tumor-matrix interface
-
R.D. Sanderson, and R.V. Iozzo Targeting heparanase for cancer therapy at the tumor-matrix interface Matrix Biol 31 2012 283 284
-
(2012)
Matrix Biol
, vol.31
, pp. 283-284
-
-
Sanderson, R.D.1
Iozzo, R.V.2
-
20
-
-
20144388264
-
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting
-
A. Naggi, B. Casu, M. Perez, G. Torri, G. Cassinelli, and S. Penco Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting J Biol Chem 280 2005 12103 12113
-
(2005)
J Biol Chem
, vol.280
, pp. 12103-12113
-
-
Naggi, A.1
Casu, B.2
Perez, M.3
Torri, G.4
Cassinelli, G.5
Penco, S.6
-
22
-
-
79951676056
-
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
-
K. Dredge, E. Hammond, P. Handley, T.J. Gonda, M.T. Smith, and C. Vincent PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models Br J Cancer 104 2011 635 642
-
(2011)
Br J Cancer
, vol.104
, pp. 635-642
-
-
Dredge, K.1
Hammond, E.2
Handley, P.3
Gonda, T.J.4
Smith, M.T.5
Vincent, C.6
-
23
-
-
79959266354
-
M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis
-
H. Zhou, S. Roy, E. Cochran, R. Zouaoui, C.L. Chu, and J. Duffner M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis PLoS ONE 6 2011 e21106
-
(2011)
PLoS ONE
, vol.6
, pp. 21106
-
-
Zhou, H.1
Roy, S.2
Cochran, E.3
Zouaoui, R.4
Chu, C.L.5
Duffner, J.6
-
24
-
-
79952731895
-
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis
-
J.P. Ritchie, V.C. Ramani, Y. Ren, A. Naggi, G. Torri, and B. Casu SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis Clin Cancer Res 17 2011 1382 1393
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1382-1393
-
-
Ritchie, J.P.1
Ramani, V.C.2
Ren, Y.3
Naggi, A.4
Torri, G.5
Casu, B.6
-
25
-
-
79955866633
-
Preclinical and clinical significante of heparanase in Ewing sarcoma
-
I. Shafat, M.W. Bern-Arush, J. Issakov, I. Meller, I. Naroditsky, and M. Tortoreto Preclinical and clinical significante of heparanase in Ewing sarcoma J Cell Mol Med 115 2011 1857 1864
-
(2011)
J Cell Mol Med
, vol.115
, pp. 1857-1864
-
-
Shafat, I.1
Bern-Arush, M.W.2
Issakov, J.3
Meller, I.4
Naroditsky, I.5
Tortoreto, M.6
-
26
-
-
70349849375
-
Heparanase activity in alveolar and embryonal rhabdomyosarcoma: Implications for tumor invasion
-
V. Masola, C. Maran, E. Tassone, A. Zin, A. Rosolen, and M. Onisto Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion BMC Cancer 9 2009 304 313
-
(2009)
BMC Cancer
, vol.9
, pp. 304-313
-
-
Masola, V.1
Maran, C.2
Tassone, E.3
Zin, A.4
Rosolen, A.5
Onisto, M.6
-
27
-
-
84861234062
-
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects
-
G. Cassinelli, V. Zuco, G. Petrangolini, M. De Cesare, M. Tortoreto, and C. Lanzi The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects Biochem Pharmacol 84 2012 163 171
-
(2012)
Biochem Pharmacol
, vol.84
, pp. 163-171
-
-
Cassinelli, G.1
Zuco, V.2
Petrangolini, G.3
De Cesare, M.4
Tortoreto, M.5
Lanzi, C.6
-
28
-
-
58349113405
-
Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: A putative mechanism
-
X. Zheng, F. Chu, P.M. Chou, C. Gallati, U. Dier, and B.L. Mirkin Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism Am J Physiol Cell Physiol 296 2009 C65 C74
-
(2009)
Am J Physiol Cell Physiol
, vol.296
-
-
Zheng, X.1
Chu, F.2
Chou, P.M.3
Gallati, C.4
Dier, U.5
Mirkin, B.L.6
-
29
-
-
16844366948
-
Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing's sarcoma family
-
S. Dalal, A.M. Berry, C.J. Cullinane, D.C. Mangham, R. Grimer, and I.J. Lewis Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family Clin Cancer Res 11 2005 2364 2378
-
(2005)
Clin Cancer Res
, vol.11
, pp. 2364-2378
-
-
Dalal, S.1
Berry, A.M.2
Cullinane, C.J.3
Mangham, D.C.4
Grimer, R.5
Lewis, I.J.6
-
30
-
-
65249103282
-
Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metallo proteinases
-
E. Zcharia, J. Jia, X. Zhang, L. Baraz, U. Lindahl, and T. Peretz Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metallo proteinases PLoS ONE 4 2009 e5181
-
(2009)
PLoS ONE
, vol.4
, pp. 5181
-
-
Zcharia, E.1
Jia, J.2
Zhang, X.3
Baraz, L.4
Lindahl, U.5
Peretz, T.6
-
31
-
-
57749101252
-
Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma
-
A. Purushothaman, L. Chen, Y. Yang, and R.D. Sanderson Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma J Biol Chem 283 2008 32628 32636
-
(2008)
J Biol Chem
, vol.283
, pp. 32628-32636
-
-
Purushothaman, A.1
Chen, L.2
Yang, Y.3
Sanderson, R.D.4
-
32
-
-
28044442504
-
Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies
-
R.D. Sanderson, Y. Yang, T. Kelly, V. MacLeod, Y. Dai, and A. Theus Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies J Cell Biochem 96 2005 897 905
-
(2005)
J Cell Biochem
, vol.96
, pp. 897-905
-
-
Sanderson, R.D.1
Yang, Y.2
Kelly, T.3
MacLeod, V.4
Dai, Y.5
Theus, A.6
-
33
-
-
77955055849
-
Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Racl pathway
-
S. Kamura, Y. Matsumoto, J-I. Fukushi, T. Fujiwara, K. Iida, and Y. Okada Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Racl pathway Br J Cancer 103 2010 370 381
-
(2010)
Br J Cancer
, vol.103
, pp. 370-381
-
-
Kamura, S.1
Matsumoto, Y.2
Fukushi, J.-I.3
Fujiwara, T.4
Iida, K.5
Okada, Y.6
-
34
-
-
77149144111
-
Antiangiogenesis agents in the treatment of soft tissue sarcomas
-
K. Ganjoo, and C. Jacobs Antiangiogenesis agents in the treatment of soft tissue sarcomas Cancer 116 2010 1177 1183
-
(2010)
Cancer
, vol.116
, pp. 1177-1183
-
-
Ganjoo, K.1
Jacobs, C.2
-
35
-
-
47149093742
-
Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas
-
H.R. Park, K. Min, H.S. Kim, W.W. Jung, and Y.K. Park Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas Pathol Res Pract 204 2008 575 582
-
(2008)
Pathol Res Pract
, vol.204
, pp. 575-582
-
-
Park, H.R.1
Min, K.2
Kim, H.S.3
Jung, W.W.4
Park, Y.K.5
-
36
-
-
28544444282
-
Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid
-
M.F. Gee, R. Tsuchida, C. Eichler-Jonsson, B. Das, S. Barichel, and D. Malkin Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid Oncogene 24 2005 8025 8037
-
(2005)
Oncogene
, vol.24
, pp. 8025-8037
-
-
Gee, M.F.1
Tsuchida, R.2
Eichler-Jonsson, C.3
Das, B.4
Barichel, S.5
Malkin, D.6
-
37
-
-
10744225880
-
Undersulfated and glycol-split heparins endowed with antiangiogenic activity
-
B. Casu, M. Guerrini, S. Guglieri, A. Naggi, M. Perez, and G. Torri Undersulfated and glycol-split heparins endowed with antiangiogenic activity J Med Chem 47 2004 838 848
-
(2004)
J Med Chem
, vol.47
, pp. 838-848
-
-
Casu, B.1
Guerrini, M.2
Guglieri, S.3
Naggi, A.4
Perez, M.5
Torri, G.6
-
38
-
-
20844441407
-
Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist
-
C. Pisano, C. Aulicino, L. Vesci, B. Casu, A. Naggi, and G. Torri Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist Glycobiology 15 2005 1C 6C
-
(2005)
Glycobiology
, vol.15
-
-
Pisano, C.1
Aulicino, C.2
Vesci, L.3
Casu, B.4
Naggi, A.5
Torri, G.6
-
39
-
-
84861158485
-
Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors
-
Y. Bai, J. Li, B. Fang, A. Edwards, G. Zhang, and M. Bui Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors Cancer Res 72 2012 2501 2511
-
(2012)
Cancer Res
, vol.72
, pp. 2501-2511
-
-
Bai, Y.1
Li, J.2
Fang, B.3
Edwards, A.4
Zhang, G.5
Bui, M.6
-
41
-
-
84860366086
-
Antiangiogenic therapy-evolving view based on clinical trial results
-
G.C. Jayson, D.J. Hicklin, and L.M. Ellis Antiangiogenic therapy-evolving view based on clinical trial results Nature Rev 9 2012 297 303
-
(2012)
Nature Rev
, vol.9
, pp. 297-303
-
-
Jayson, G.C.1
Hicklin, D.J.2
Ellis, L.M.3
|